TP53 and endometrial cancer: The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) algorithm evaluates POLE mutation, p53 and MMR expression analyses to sequentially assess the MMRd group, then POLE mutant and finally aberrant p53 cases; the remaining tumors are considered p53 normal.14, 15